ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

aprocitentan

Also written as “Aprocitentan”, “Aprocitentan 25 mg” and “Aprocitentan tablets(SYH9108)”.

Its studies are mostly in Hypertension · Liver Diseases · Essential Hypertension · Renal Insufficiency, led by 2 companies.

Drug pageAprocitentan: every studyAll 14 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since May 17, 201814 company-led studies, 1 open or runningNext primary completion: Dec 28, 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Idorsia Pharmaceuticalsits history only130 open or runningphase 3since May 17, 2018Nov 9, 2015none ahead
CSPC Pharmaceutical Group11 open or runningphase 3since May 29, 2026May 29, 2026Dec 28, 2029phase 3 · NCT07635914

Also a collaborator on its studies: Johnson & Johnson.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of CSPC Pharmaceutical Group only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2016Named aprocitentanINNProposed as its International Nonproprietary Name in WHO's List 116
  2. May 29, 2026First study: phase 3 study in Resistant HypertensionFirst studyNCT07635914 · 382 planned

Ahead

  1. Dec 28, 2029Primary completion: phase 3 study in Resistant HypertensionNCT07635914

TargetBeta

EDNRA →EDNRB →read by rule
“Endothelin receptor, ET-A/ET-B antagonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
BosentanruleJohnson & Johnsonphase 437

Studies

The one study CSPC Pharmaceutical Group leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07635914Resistant Hypertension3Not yet recruitingDec 28, 2029382

How it is read

Names in the registry

  • “Aprocitentan”, 5 entries
  • “Aprocitentan 25 mg”, 4 entries
  • “Aprocitentan tablets(SYH9108)”, 1 entry
  • “Aprocitentan 12.5 mg”, 1 entry
  • “14C-radiolabeled ACT-132577”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.